Evidence map›Paper›PMID 41246661›Full record

ArticleCureus2025

Recurrence of Atypical Meningioma: A Case Report.

Anand Paul, Shilpa Johnson, Shahina M Patel

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anand PaulRadiation Oncology, Government Medical College, Thiruvananthapuram, Trivandrum, IND.
Shilpa JohnsonInternal Medicine, Royal Blackburn Teaching Hospital, Blackburn, GBR.
Shahina M PatelGeneral Internal Medicine, Royal Blackburn Teaching Hospital, Blackburn, GBR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atypical meningiomas are classified by the World Health Organization (WHO) as grade II central nervous system tumors, representing an intermediate biological profile between benign (grade I) and anaplastic (grade III) variants. They are defined by elevated mitotic activity, invasive growth patterns, and distinct histopathological features such as hypercellularity, small cell morphology, prominent nucleoli, and areas of necrosis. Clinically, these tumors often manifest with neurological symptoms - headaches, seizures, focal neurological deficits, personality alterations, or visual impairment - depending on their anatomical location. On imaging, atypical meningiomas typically show either homogeneous or heterogeneous contrast enhancement, surrounding edema, and exert mass effect on adjacent brain structures. MRI and MR spectroscopy help in assessing these cases. Surgery tends to be the main treatment, but recurrence is more common than what's typically seen in grade I meningiomas. Adjuvant radiotherapy is frequently recommended, particularly in cases of subtotal resection or when high-risk features are present. Given their aggressive behavior and propensity for recurrence or malignant progression, comprehensive multidisciplinary care and close surveillance are critical to achieving optimal clinical outcomes. In this case, we present a 57-year-old gentleman diagnosed with peritorcular meningioma.

Indexed as

cns cancerlinac-based sbrtneuro oncologyneurosurgeryradiation oncology

Identifiers

PMID41246661
PMCPMC12618948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.